Tackling COVID‐19 Using Remdesivir and Favipiravir as Therapeutic Options

The human world is currently influenced largely by the outbreak of pandemic COVID‐19. At this moment, most researchers focus on developing treatment strategies and measures to work against COVID‐19. Treatment strategies specific for COVID‐19 are lacking. This article provides an overview of the life cycle and routes of transmission of SARS‐CoV‐2. The therapeutic effects of two drugs [i. e., remdesivir (RDV) and favipiravir (FPV)] which can potentially tackle COVID‐19 are discussed based on current published data. This review can serve as a reference for future studies. COVID‐19 is a pandemic that requires global action. This review presents the latest status of research on the use of two drugs (favipiravir and remdesivir) in tackling COVID‐19, and offers an overview of the life cycle and routes of transmission of SARS‐CoV‐2. It is hoped that the opportunities and challenges brought about by the use of these two drugs can be illuminated for future research.